A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

"A PHASE 2 RANDOMIZED, DOUBLE-BLINE PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION.

Intervention/treatment:
RO6876802 (MHAA4549A)/ OSELTAMIVIR
Medical condition:
INFLUENZA
Protocol code:
GV29216
Control number:
177867
Status:
Closed
Approved:
October 10, 2014
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT02293863
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Medical Communications
Organization
Hoffmann-La Roche
Phone:
800 821-8590
Sponsor
GENENTECH INC

Locations

Alberta

Alberta Health Services
Calgary, Alberta, T2N 4N2
Foothills Medical Centre
Calgary, Alberta, T2N 4Z6
Peter Lougheed Centre
Calgary, Alberta, T1Y 6J4
Rockyview General Hospital
Calgary, Alberta, T2V 1P9

British Columbia

Royal Columbian Hospital
New Westminster, British Columbia, V3L 3W7
Royal Jubilee Hospital Victoria general Hospital
Victoria, British Columbia, V8R 1J8
St. Paul's Hospital, Providence Health Care
Vancouver, British Columbia, V6Z 1Y6
Victoria General Hospital
Victora, British Columbia, V8Z 6R5

New Brunswick

Moncton Hospital
Moncton, New Brunswick, E1C 6Z8

Ontario

Lakeridge Health
Oshawa, Ontario, L1G 2B9
LHSC - University Hospital; Research Pharmacy
London, Ontario, N6A 5A5
Ottawa Hospital Research Institute
Ottawa, Ontario, K1Y 4E9
The Ottawa Hospital - Civic Campus
Ottawa, Ontario, K1Y 4E9
Toronto East General
Toronto, Ontario, M4C 3E7
Toronto Western Hospital
Toronto, Ontario, M5T 2S8
University Health Network
Toronto, Ontario, M5G 2N2

Quebec

Centre de santé et de services sociaux de Trois-Rivières
Trois-Rivières, Quebec, G9A1Y1
Centre Hospitalier de la Universite Laval
Québec, Quebec, G1V 4G5
Pavillion Chul-Chuq
Sainte-Foy, Quebec, G1V 4G2

Results

See the results from the trial NCT02293863. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?